# Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects

> **NCT02876796** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 30 (actual)

## Conditions studied

- PD Effects of GS-0976 (NDI-010976) on Fractional DNL

## Interventions

- **DRUG:** GS-0976
- **DRUG:** Placebo
- **OTHER:** 1-13C acetate
- **OTHER:** Fructose solution

## Key facts

- **NCT ID:** NCT02876796
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2015-09
- **Final completion:** 2015-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02876796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02876796, "Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02876796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*